Cardinal Health (CAH) is back in focus after expanding Actinium-225 production at its Center for Theranostics Advancement in Indianapolis. This move is aimed at supplying more material for investigational and future commercial cancer therapies.

Recent news around Actinium-225 expansion and a board leadership change comes as Cardinal Health’s share price sits at US$214.05, with a 1-year share price return and a very large 5-year total shareholder return of about 4x. This suggests momentum has been building over time.

If you are looking at how cancer care and therapies are evolving, it can be useful to see which other companies are gaining attention in related areas, including 36 healthcare AI stocks.

With Cardinal Health shares at US$214.05 after a strong multi year run and analysts’ average price target at US$249.60, the key question is whether there is still upside or if the market is already pricing in future growth.

Most Popular Narrative: 14.2% Undervalued

Cardinal Health’s most followed narrative points to a fair value of $249.60 versus the last close at $214.05, framing the recent share price strength in a valuation gap context.

The strong performance and continued investment in Other growth businesses such as at-Home Solutions, Nuclear and Precision Health, and OptiFreight Logistics aligns with the growing trend of outpatient and home healthcare, underpinning diversified revenue growth and supporting margin expansion.

Curious what sits behind that valuation gap? The narrative leans on tightly modelled revenue expansion, modest margin lift, and a richer earnings multiple than the sector. The mix really matters here.

Result: Fair Value of $249.60 (UNDERVALUED)

However, you still need to watch for tighter regulation and pricing scrutiny, as well as the risk that major customer contract changes could unsettle that undervaluation story.

Another Take: Rich P/E Against Peers

While the most followed narrative points to undervaluation, Cardinal Health trades on a P/E of 30.3x versus 21.7x for the wider US Healthcare group and 24.2x for peers, only slightly below its fair ratio of 31.2x. That suggests less obvious room for error if sentiment cools.

To see what the numbers say if this price sticks, and where the market P/E could shift next, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

That mix of optimism and caution around Cardinal Health can feel finely balanced, so it makes sense to move quickly, test the data yourself, and weigh up the 3 key rewards and 2 important warning signs.

Ready to uncover more investment ideas?

If Cardinal Health has caught your eye, do not stop there; broaden your watchlist with a few focused stock ideas that could sharpen your next move.

• Target potential mispricing by scanning for companies that combine strong fundamentals with attractive valuations using the 58 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with resilient payout profiles through the 13 dividend fortresses.
• Stay on the front foot by checking a curated set of stocks with robust balance sheets via the solid balance sheet and fundamentals stocks screener (40 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.